ArticleAllergy2026
Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS).
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundA complex interaction between environmental and lifestyle factors, immune dysregulation, and skin barrier integrity is believed to contribute to the development of atopic dermatitis (AD). However, the precise mechanisms underlying disease onset in infants remain largely unclear.
methodsThe "Munich Atopic Prediction Study" (MAPS) is a comprehensive clinical and biological investigation of a prospective birth cohort from Munich, Germany. Information on pregnancy, child development, environmental influences, parental exposure to potential allergens, as well as illnesses affecting both children and parents is gathered through questionnaires. This is complemented by thorough clinical examinations conducted by trained dermatologists, with a particular focus on allergies and skin health. Biomarker analyses were performed, for example, on cord blood immune cells using flow cytometry (FACS analysis).
resultsMaternal AD (aOR = 3.06, p = 0.020) and affected siblings (aOR = 4.80, p = 0.039) are associated with an increased risk of AD, whereas cold-remedy intake showed a protective association (aOR = 0.11, p = 0.047). Infants later diagnosed with AD (total 74 infants, AD n = 27, healthy n = 47) are characterized by reduced frequencies of CD4
conclusionOur study identifies early immune alterations, particularly a reduction in cord blood Breg cells, as potential contributors to AD pathogenesis. Incorporating Breg-cell measurements into neonatal immune panels, along with key perinatal and familial risk factors, may enhance early risk stratification and enable more personalized prevention of atopic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.